Clinical trials: Cancer Brain
Metastatic Breast Cancer
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer
- Trial name
- DB-07 (NCT04538742)
- Testing
- Trastuzumab deruxtecan, Durvalumab, Paclitaxel
- Where
- 72 sites in United States, Australia and 13 more
- Volunteers
- 245 people
- Sponsor
- AstraZeneca
Neoplasms, Breast
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
Determine how safe and effective lapatinib is when used to treat patients with ErbB2 overexpressing breast cancer that has spread to the brain and is still progressing there even after radiation treatment using WBRT (whole brain…
- Trial name
- NCT00263588
- Testing
- lapatinib
- Where
- 74 sites in United States, Australia and 15 more
- Volunteers
- 242 people
- Sponsor
- Novartis Pharmaceuticals
Brain Tumor, Glioma, Malignant
Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
Pear Bio has developed a 3D microtumor assay and computer vision pipeline through which the response of an individual patient's tumor to different anti-cancer regimens can be tested simultaneously ex vivo.
- Conditions
- Brain Tumor, Glioma, Malignant, Ependymoma, Oligodendroglioma
- Trial name
- PEAR-GLIO (NCT06038760)
- Testing
- Resection
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Ourotech, Inc.
Pituitary Tumors
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors
Many types of cancers overexpress a receptor for the vitamin folate (Folate Receptor). This Phase 2 study will utilize a standard imaging radionuclide, technetium-99m, conjugated to a ligand (EC20) designed to bind to the folate…
- Trial name
- NCT01689727
- Testing
- Technetium Tc 99m EC20
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Endocyte
Central Nervous System (CNS) Lesions, Brain Metastases
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain tumors or multiple sclerosis.
- Conditions
- Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms, Brain Neoplasms, Benign
- Trial name
- NCT06322342
- Testing
- RVP-001
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Reveal Pharmaceuticals Inc.
Central Nervous System Neoplasms, Medulloblastoma
A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
This study will assess the efficacy, safety and tolerability of pomalidomide in children and young adults aged 1 to < 21 years with recurrent or progressive primary brain tumors in one of four primary brain tumor types…
- Trial name
- NCT03257631
- Testing
- Pomalidomide
- Where
- 22 sites in United States, France and 3 more
- Volunteers
- 53 people
- Sponsor
- Celgene
Advanced Cancer
DM-CHOC-PEN Plus Radiation for Brain Tumors
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a polychlorinated pyridyl cholesterol carbonate that is lipophilic, electrically neural, crosses the blood brain barrier (BBB), ability to localize in intracranial…
- Trial name
- NCT03371004
- Testing
- 4-Demethyl-4-cholesteryloxycarbonylpenclomedine
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- DEKK-TEC, Inc.
Brain Neoplasms, Malignant Neoplasms, Brain
Study of Karenitecin (BNP1350) in Patients With Brain Tumors
The purpose of this study is to evaluate safety and efficacy ofKarenitecin (BNP1350) as a treatment of adults with brain tumors.
- Conditions
- Brain Neoplasms, Malignant Neoplasms, Brain, Brain Tumors
- Trial name
- NCT00062478
- Testing
- Karenitecin (BNP1350)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- BioNumerik Pharmaceuticals, Inc.
Metastatic Brain Tumors, Progression
Laser Ablation After Stereotactic Radiosurgery
The need for new technologies and devices in the field of neurosurgery is well established. In April 2013, FDA cleared NeuroBlate™ System, minimally invasive robotic laser thermotherapy tool.
- Conditions
- Metastatic Brain Tumors, Progression, Radiation Necrosis, Quality of Life
- Trial name
- LAASR (NCT01651078)
- Where
- 7 sites in United States
- Volunteers
- 44 people
- Sponsor
- Monteris Medical
Brain Metastases From Solid Tumors
Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
This is an open-label, single dose, single arm, multicenter Phase 2b study to establish the imaging performance of RAD101 PET in participants who are ≥ 18 years of age and with suspected recurrent brain metastases from solid…
- Trial name
- RAD101 (NCT06777433)
- Testing
- RAD101 (18F-FPIA)
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Radiopharm Theranostics, Ltd
Cancer, Solid Tumor
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Trial name
- NCT05500508
- Testing
- AMXT1501, DFMO
- Where
- 7 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Aminex Therapeutics, Inc.
Progressive Pediatric Brain Cancer
Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer
This is a open label Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of NLG802, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme, in…
- Trial name
- NCT07732413
- Testing
- NLG802 (indoximod Prodrug), Temozolomide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Lumos Pharma
Recurrent Glioblastoma
Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma
The purpose of this clinical study is to confirm the utility of chemosensitivity tumor testing on cancer stem cells (ChemoID) as a predictor of clinical response in poor prognosis malignant brain tumors such as recurrent…
- Trial name
- CSCRGBM (NCT03632135)
- Testing
- ChemoID assay, Chemotherapy
- Where
- 13 sites in United States
- Volunteers
- 78 people
- Sponsor
- Cordgenics, LLC
Alzheimer's Disease
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose.
- Trial name
- REFLECT-3 (NCT00348140)
- Testing
- Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg
- Where
- 194 sites in United States, Australia and 20 more
- Volunteers
- 1,468 people
- Sponsor
- GlaxoSmithKline
Brain and Central Nervous System Tumors
Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. This may be an effective treatment for some types of brain tumors.
- Trial name
- NCT00004017
- Testing
- conventional surgery, iodine I 131 monoclonal antibody TNT-1/B
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Peregrine Pharmaceuticals
Glioblastoma
A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme
The purpose of the study is to determine the efficacy of gefitinib (IressaTM) in combination with radiotherapy on patients with glioblastoma multiforme.
- Trial name
- NCT00238797
- Testing
- Gefitinib
- Where
- 3 sites in Sweden
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
Glioblastoma Multiforme
The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme
The purpose of the PRECISE trial is to determine whether overall survival duration, safety, and quality of life are improved for patients treated with IL13-PE38QQR compared to patients treated with GLIADEL® Wafer following…
- Trial name
- NCT00076986
- Testing
- IL13-PE38QQR, surgery and catheter placement (2 procedures), prolifespan 20 with carmustine implant (GLIADEL® Wafer)
- Where
- 60 sites in United States, Canada and 4 more
- Volunteers
- 300 people
- Sponsor
- INSYS Therapeutics Inc
Refractory Solid Tumors
Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors
Phase 1, Multiple Dose Study of MPC-6827 in Subjects with Refractory Solid Tumors.
- Trial name
- NCT00394446
- Testing
- MPC-6827
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Myrexis Inc.
Glioblastoma Multiforme, Brain Tumor
Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients
This study is to evaluate the safety and find the tolerated ultrasound dose of transient opening of the blood-brain barrier (BBB) by using the NaviFUS System in recurrent GBM patients.
- Conditions
- Glioblastoma Multiforme, Brain Tumor, Glioblastoma, Glioma
- Trial name
- NCT03626896
- Testing
- NaviFUS System
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- NaviFUS Corporation
Brain Cancer
PET Imaging of Intracranial Cancers With 18F-FSPG
The aim of this study is to explore the efficacy of 18F-FSPG in the detection of primary or metastatic brain cancer lesions confirmed by a standard of truth, preferably histology.
- Trial name
- NCT02370563
- Testing
- 18F-FSPG
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Lantheus Biosciences Ltd.